RBC Capital Maintains Outperform on Thermo Fisher Scientific, Lowers Price Target to $718
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Conor McNamara maintains an Outperform rating on Thermo Fisher Scientific (NYSE:TMO) but lowers the price target from $767 to $718.
October 24, 2024 | 5:47 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
RBC Capital has maintained its Outperform rating for Thermo Fisher Scientific but has reduced the price target from $767 to $718, indicating a more cautious outlook.
The maintenance of an Outperform rating suggests continued confidence in TMO's performance, but the lowered price target indicates a more cautious outlook, likely due to market conditions or company-specific factors. This could lead to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100